ABOT Abbott Laboratories (Pakistan) Limited
Latest results: FY2025 · Dec 2025 Q2 FY2026 · Apr – Jun 2026
Last close · 16 Oct 2026
Rs 944.39 +1.11%
Annual · FY2006 – FY2025
Abbott Laboratories (Pakistan) Limited (ABOT) financial ratios
Abbott Laboratories (Pakistan) Limited earned a net margin of 10.6% in FY2025 against a five-year average of 7.8% (Pharmaceuticals median 9.4%). Return on equity was 28.8%, compared with a sector median of 21.7%. The current ratio stood at 2.32× and debt was 1.5% of equity. Cash took about 82 days to cycle through receivables, inventory and payables.
FY2025 vs the Pharmaceuticals median
- Gross margin
- 35.5%
- Sector median 37.0%
- Operating margin
- 17.5%
- Sector median 17.3%
- Net margin
- 10.6%
- Sector median 9.4%
- Return on equity (ROE)
- 28.8%
- Sector median 21.7%
- Return on assets (ROA)
- 18.9%
- Sector median 11.7%
- Current ratio
- 2.32×
- Sector median 1.79×
- Debt to equity
- 1.5%
- Sector median 5.8%
- Asset turnover
- 1.79×
- Sector median 1.26×
- Dividend payout ratio
- 49.2%
- Sector median 32.8%
Median of the 14 companies in the sector with the figure for their latest fiscal year.
| Rs mn | FY2025 Jan – Dec 2025 | FY2024 Jan – Dec 2024 | FY2023 Jan – Dec 2023 | FY2022 Jan – Dec 2022 | FY2021 Jan – Dec 2021 | FY2020 Jan – Dec 2020 | FY2019 Jan – Dec 2019 | FY2018 Jan – Dec 2018 | FY2017 Jan – Dec 2017 | FY2016 Jan – Dec 2016 | FY2015 Jan – Dec 2015 | FY2014 Jan – Dec 2014 | FY2013 Jan – Dec 2013 | FY2012 Jan – Dec 2012 | FY2011 Jan – Dec 2011 | FY2010 Jan – Dec 2010 | FY2009 Dec 2008 – Nov 2009 | FY2008 * Dec 2007 – Nov 2008 | FY2007 * Dec 2006 – Nov 2007 | FY2006 Dec 2005 – Nov 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||
| Gross margin | 35.5% | 29.3% | 21.3% | 29.5% | 37.8% | 34.6% | 28.3% | 33.0% | 38.7% | 40.1% | 38.9% | 38.3% | 38.5% | 37.5% | 36.0% | 33.5% | 27.5% | 29.9% | 41.4% | 41.2% |
| EBITDA margin | 20.0% | 15.7% | 8.6% | 15.3% | 21.3% | 20.4% | 11.8% | 17.2% | 23.5% | 24.6% | 24.0% | 21.9% | 22.7% | 21.2% | 19.8% | 28.7% | 23.4% | 24.8% | 36.1% | 27.4% |
| Operating margin | 17.5% | 13.0% | 5.8% | 12.4% | 18.3% | 17.2% | 8.4% | 14.7% | 21.2% | 22.3% | 21.7% | 19.7% | 20.4% | 19.0% | 17.6% | 26.4% | 20.9% | 22.0% | 33.3% | 24.0% |
| Pre-tax margin | 17.9% | 13.2% | 3.7% | 12.5% | 19.8% | 17.7% | 8.3% | 14.6% | 22.4% | 23.9% | 23.6% | 21.9% | 21.4% | 19.8% | 18.3% | 15.8% | 10.4% | 7.6% | 26.5% | 23.9% |
| Net margin | 10.6% | 7.7% | 0.5% | 6.1% | 14.0% | 12.9% | 4.3% | 9.1% | 16.1% | 17.2% | 16.9% | 14.3% | 14.7% | 13.7% | 12.7% | 10.7% | 7.2% | 4.8% | 18.0% | 16.9% |
| Effective tax rate | 41.0% | 42.0% | 87.2% | 51.1% | 29.1% | 27.4% | 48.2% | 38.0% | 28.0% | 28.0% | 28.4% | 34.8% | 31.4% | 30.7% | 30.7% | 32.4% | 30.5% | 36.9% | 32.1% | 29.3% |
| Returns | ||||||||||||||||||||
| Return on equity (ROE) | 28.8% | 24.9% | 1.5% | 17.4% | 36.2% | 31.3% | 9.8% | 19.5% | 29.1% | 29.2% | 30.1% | 28.7% | 32.7% | 35.1% | 36.1% | 32.9% | 17.9% | 9.5% | 29.9% | 20.4% |
| Return on assets (ROA) | 18.9% | 14.1% | 0.7% | 9.6% | 22.3% | 19.9% | 6.3% | 13.7% | 22.8% | 23.6% | 23.7% | 22.6% | 24.7% | 25.0% | 24.9% | 21.9% | 12.2% | 7.1% | 24.4% | 17.1% |
| Return on invested capital (ROIC) | 28.6% | 24.9% | 1.5% | 17.3% | 35.3% | 30.4% | 9.7% | 19.4% | 29.1% | 29.2% | 30.1% | 28.7% | 32.7% | 35.1% | 36.1% | 32.9% | 17.9% | 9.5% | 29.9% | 20.4% |
| Liquidity | ||||||||||||||||||||
| Current ratio | 2.32× | 1.99× | 1.38× | 1.49× | 1.97× | 2.30× | 1.80× | 1.96× | 2.98× | 4.61× | 3.73× | 3.86× | 3.56× | 2.71× | 2.42× | 2.19× | 2.03× | 2.50× | 3.55× | 4.76× |
| Quick ratio | 1.34× | 1.03× | 0.59× | 0.89× | 1.22× | 1.53× | 0.88× | 1.27× | 2.19× | 3.31× | 2.81× | 2.76× | 2.27× | 1.66× | 1.26× | 0.97× | 0.94× | 1.24× | 1.95× | 3.01× |
| Leverage | ||||||||||||||||||||
| Debt to equity | 1.5% | 0.2% | 0.9% | 1.4% | 1.3% | 5.2% | 2.9% | 1.6% | 0.0% | — | — | — | — | — | — | — | — | — | 0.0% | 0.1% |
| Debt to capital | 1.5% | 0.2% | 0.9% | 1.4% | 1.3% | 5.0% | 2.8% | 1.6% | 0.0% | — | — | — | — | — | — | — | — | — | 0.0% | 0.1% |
| Debt to assets | 1.0% | 0.1% | 0.4% | 0.7% | 0.8% | 3.3% | 1.8% | 1.1% | 0.0% | — | — | — | — | — | — | — | — | — | 0.0% | 0.1% |
| Assets to equity | 1.53× | 1.77× | 2.00× | 1.81× | 1.62× | 1.58× | 1.54× | 1.43× | 1.27× | 1.24× | 1.27× | 1.27× | 1.33× | 1.41× | 1.45× | 1.50× | 1.47× | 1.34× | 1.23× | 1.20× |
| Efficiency | ||||||||||||||||||||
| Asset turnover | 1.79× | 1.83× | 1.57× | 1.58× | 1.59× | 1.55× | 1.47× | 1.51× | 1.42× | 1.37× | 1.40× | 1.58× | 1.68× | 1.82× | 1.96× | 2.04× | 1.69× | 1.46× | 1.36× | 1.01× |
| Receivable days days | 24 | 27 | 25 | 21 | 22 | 28 | 29 | 21 | 17 | 16 | 14 | 17 | 22 | 25 | 25 | 25 | 25 | 26 | 31 | 39 |
| Inventory days days | 92 | 93 | 93 | 84 | 84 | 92 | 93 | 75 | 83 | 88 | 85 | 87 | 93 | 95 | 100 | 105 | 104 | 116 | 129 | 173 |
| Payable days days | 34 | 54 | 70 | 56 | 42 | 36 | 44 | 44 | 31 | 24 | 20 | 16 | 20 | 19 | 17 | 20 | 20 | 19 | 22 | 26 |
| Cash conversion cycle days | 82 | 66 | 48 | 49 | 64 | 84 | 78 | 52 | 70 | 79 | 78 | 88 | 95 | 101 | 108 | 109 | 109 | 122 | 137 | 186 |
| Dividends | ||||||||||||||||||||
| Dividend payout ratio | 49.2% | 18.7% | 0.0% | 48.9% | 65.6% | 86.3% | 56.5% | 72.7% | 93.1% | 97.4% | 81.9% | 27.1% | 27.1% | 32.8% | 35.7% | 41.6% | 192.9% | 142.3% | 148.7% | 21.7% |
| Earnings retention rate | 0.51× | 0.81× | 1.00× | 0.51× | 0.34× | 0.14× | 0.44× | 0.27× | 0.07× | 0.03× | 0.18× | 0.73× | 0.73× | 0.67× | 0.64× | 0.58× | (0.93×) | (0.42×) | (0.49×) | 0.78× |
Ratios as reported for each fiscal year; returns are on average equity / assets. Debt ratios are percentages; turnover in times; working-capital measures in days.
ABOT: frequently asked questions
What is ABOT's EPS?
Abbott Laboratories (Pakistan) Limited reported basic earnings per share of Rs 81.37 for FY2025 (Jan – Dec 2025). Over the trailing twelve months (TTM to Jun 2026) EPS was Rs 87.47.
What is ABOT's P/E ratio?
At the closing price of Rs 944.39 on 16 Oct 2026, ABOT trades at a P/E of 10.8× based on EPS of Rs 87.47 (TTM to Jun 2026).
Does ABOT pay dividends?
Yes. Abbott Laboratories (Pakistan) Limited declared a dividend of Rs 40.00 per share for FY2025. It has paid a dividend in each of the last 2 years. At Rs 944.39 that is a dividend yield of 4.2%.
What was ABOT's revenue and profit in FY2025?
Abbott Laboratories (Pakistan) Limited reported revenue of Rs 75.4 bn and profit attributable to shareholders of Rs 8.0 bn for FY2025 (Jan – Dec 2025).
What is ABOT's book value per share?
Abbott Laboratories (Pakistan) Limited's book value per share was Rs 323.04 at the end of FY2025. The shares trade at 2.88× book value.
Information only, not investment advice.